Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

✍ Scribed by Gaudet, Daniel; Kereiakes, Dean J.; McKenney, James M.; Roth, Eli M.; Hanotin, Corinne; Gipe, Daniel; Du, Yunling; Ferrand, Anne-Catherine; Ginsberg, Henry N.; Stein, Evan A.

• Book ID: 125859998
• Publisher: Elsevier Science
• Year: 2014
• Tongue: English
• Weight: 509 KB
• Volume: 114
• Category: Article
• ISSN: 0002-9149
• DOI: 10.1016/j.amjcard.2014.05.060